Hi Index…,batch to batch consistency was an issue along with evidence of MOA. Regarding the trial….Ryoncil was a therapy targeted at children 12 yrs and under. There still remains no approved SOC for this demographic however a better SOC exists for adults with GVHD. Whilst the FDA expressed concerns regarding batch consistency & MOA despite a 9-1 ODAC vote in favour of approval, the FDA allowed MESO to continue to treat the 12yr & under cohort since they slapped the CRL on Msb.
Ann: Uni of Newcastle Heart Protection Collaboration Extended, page-47
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
0.000(0.00%) |
Mkt cap ! $270.9M | |||
| Open | High | Low | Value | Volume |
| $1.61 | $1.62 | $1.55 | $189.9K | 121.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1316 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 34961 | 1 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |